Adr Form Pvpi
Adr Form Pvpi
Adr Form Pvpi
A. Patient Information
1.Patient Initials _____________ 2.Age at time of Event or date of birth ------------------3. Sex M F
4. Weight ____Kgs
B .Suspected Adverse Reaction 5. Date of reaction stated (dd/mm/yyyy) 6. Date of recovery (dd/mm/yyyy) 7. Describe reaction or problem
13. Other relevant history including pre-existing medical conditions (e.g. allergies, race, pregnancy, smoking, alcohol use, hepatic/ renal dysfunction etc)
15. Outcomes
Fatal Continuing Recovering Recovered Unknown Other (specify)____
C.Suspected medication(s)
S.No
8. Name (brand and /or generic name) Manufactu rer (if known) Batch No./ Lot No. (if known) Exp. Date (if known) Dose used Route used Frequency Therapy dates (if known give duration) Date started Date stopped
Where to report:
Please return the completed form to the nearest Adverse drug reaction Monitoring Centre (AMC) or to National Coordinating Centre A list of nationwide AMCs is available at: http://cdsco.nic.in/pharmacovigilance.htm
Safety
Pharmacovigilance Programme of India (PvPI) National Coordinating Centre, Indian Pharmacopoeia Commission Ministry of Health & Family Welfare, Govt. of India
Sector-23, Raj Nagar, Ghaziabad-201 002.Tel.:01202783400, 2783401, 2783392, FAX: 0120-2783311 E.mail: ipclab@vsnl.net
Confidentiality: The patients identity is held in strict confidence and protected to the fullest extent. Programme staff is not ex- pected to and will not disclose the reporters identity in response to a request from the public. Submission of a report does not constitute an admission that medical personnel or manufacturer or the product caused or contributed to the reaction.
Information provided in this form is handled in strict confidence. The causality assessment is carried out at Adverse Drug Reaction Monitoring Centres (AMCs) by using WHO-UMC scale. The analyzed forms are forwarded to the National Coordinating Centre through the ADR database. Finally the data is analyzed and forwarded to the Global Pharmacovigilance Database managed by WHO Uppsala Monitoring Center in Sweden. The reports are periodically reviewed by the National Coordinating Centre (PvPI). The information generated on the basis of these reports helps in continuous assessment of the benefit-risk ratio of medicines. The information is submitted to the Steering Committee of PvPI constituted by the Ministry of Health and Family Welfare. The Committee is entrusted with the responsibility to review the data and suggest any interventions that may be required.